158 related articles for article (PubMed ID: 30936015)
1. Human alcohol dehydrogenase 1 is an acceptor protein for polyADP-ribosylation.
Yamashita S; Tanaka M; Nodono H; Hamada A; Hamada T; Hasegawa M; Nishi Y; Moss J; Miwa M
Biochem Pharmacol; 2019 Sep; 167():27-32. PubMed ID: 30936015
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
3. Physiological levels of poly(ADP-ribose) during the cell cycle regulate HeLa cell proliferation.
Yamashita S; Tanaka M; Ida C; Kouyama K; Nakae S; Matsuki T; Tsuda M; Shirai T; Kamemura K; Nishi Y; Moss J; Miwa M
Exp Cell Res; 2022 Aug; 417(1):113163. PubMed ID: 35447104
[TBL] [Abstract][Full Text] [Related]
4. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
Ferrarotto R; Cardnell R; Su S; Diao L; Eterovic AK; Prieto V; Morrisson WH; Wang J; Kies MS; Glisson BS; Byers LA; Bell D
Head Neck; 2018 Aug; 40(8):1676-1684. PubMed ID: 29570891
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.
Huang M; Ren J; Wang Y; Chen X; Yang J; Tang T; Yang Z; Li X; Ji M; Cai J
Chem Pharm Bull (Tokyo); 2021; 69(7):620-629. PubMed ID: 34193711
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
[TBL] [Abstract][Full Text] [Related]
7. ADP-Ribosylation as Post-Translational Modification of Proteins: Use of Inhibitors in Cancer Control.
Poltronieri P; Miwa M; Masutani M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639169
[TBL] [Abstract][Full Text] [Related]
8. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
10. Androgen signaling uses a writer and a reader of ADP-ribosylation to regulate protein complex assembly.
Yang CS; Jividen K; Kamata T; Dworak N; Oostdyk L; Remlein B; Pourfarjam Y; Kim IK; Du KP; Abbas T; Sherman NE; Wotton D; Paschal BM
Nat Commun; 2021 May; 12(1):2705. PubMed ID: 33976187
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
13. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
15. Olaparib-Based Photoaffinity Probes for PARP-1 Detection in Living Cells.
Voorneveld J; Florea BI; Bakkum T; Mendowicz RJ; van der Veer MS; Gagestein B; van Kasteren SI; van der Stelt M; Overkleeft HS; Filippov DV
Chembiochem; 2020 Sep; 21(17):2431-2434. PubMed ID: 32282108
[TBL] [Abstract][Full Text] [Related]
16. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.
Karpova Y; Wu C; Divan A; McDonnell ME; Hewlett E; Makhov P; Gordon J; Ye M; Reitz AB; Childers WE; Skorski T; Kolenko V; Tulin AV
Biochem Pharmacol; 2019 Sep; 167():149-162. PubMed ID: 30880062
[TBL] [Abstract][Full Text] [Related]
17. PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1.
Liu L; Kong M; Gassman NR; Freudenthal BD; Prasad R; Zhen S; Watkins SC; Wilson SH; Van Houten B
Nucleic Acids Res; 2017 Dec; 45(22):12834-12847. PubMed ID: 29121337
[TBL] [Abstract][Full Text] [Related]
18. A rapid fluorescent method for the real-time measurement of poly(ADP-ribose) polymerase 1 activity.
Kurgina TA; Anarbaev RO; Sukhanova MV; Lavrik OI
Anal Biochem; 2018 Mar; 545():91-97. PubMed ID: 29326071
[TBL] [Abstract][Full Text] [Related]
19. PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.
Mashimo M; Bu X; Aoyama K; Kato J; Ishiwata-Endo H; Stevens LA; Kasamatsu A; Wolfe LA; Toro C; Adams D; Markello T; Gahl WA; Moss J
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830864
[TBL] [Abstract][Full Text] [Related]
20. PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: Implications for CNS disease therapeutics.
Sinha A; Katyal S; Kauppinen TM
Neuropharmacology; 2021 Apr; 187():108502. PubMed ID: 33631119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]